medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 4

<< Back Next >>

Ann Hepatol 2015; 14 (4)

Colorectal cancer surveillance in primary sclerosing cholangitis and inflammatory bowel disease

Tabibian JH, Moradkhani A, Topazian MD

Language: English
References: 25
Page: 564-566
PDF size: 88.11 Kb.


Text Extraction

Dear Editor:
Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease which leads to end-stage cirrhosis, is a recognized risk factor for hepatobiliary and colonic carcinogenesis, and carries a median liver transplant (LT) free survival time of approximately 15 years. Due to its progressive and idiopathic nature, lack of effective pharmacotherapy, and paucity of predictors of adverse outcomes, PSC is the 5th most common indication for LT in the United States and a leading indication in several other countries worldwide.


REFERENCES

  1. Tabibian JH, Lindor KD. Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis. J Analytical Oncol 2012; 1: 50-5.

  2. Weismuller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis— aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008; 48(Suppl. 1): S38-S57.

  3. Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Dig Liver Dis 2010; 42:390-400.

  4. Jussila A, Virta LJ, Pukkala E, Farkkila MA. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol 2013; 48: 1405-13.

  5. Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA. Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Ann Hepatol 2014; 13: 384-9.

  6. UNOS. United Network for Organ Sharing. “Liver Transplants Performed for Recipients Age 18+ at Time of Transplant in the US from January 1, 2005 to October 31, 2014 by Primary Diagnosis at Time of Transplant and Year of Transplant”. Data report request. 15 January 2015. 2015.

  7. Bjoro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis 2006; 26: 69-79.

  8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

  9. Centers for Disease Control and Prevention. Inflammatory bowel disease (IBD). Available at: http://www.cdc.gov/ ibd/ibd-epidemiology.htm. Revised September 16, 2014. Accessed March 21, 2015.

  10. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54.

  11. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-08.

  12. Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U, Chapman R, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002; 37: 1205-11.

  13. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TR, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430-6.

  14. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158-64.

  15. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-7.

  16. Farraye FA, Odze RD, Eaden J, Itzkowitz SH, McCabe RP, Dassopoulos T, Lewis JD, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 738-45.

  17. Tabibian A, Tabibian JH, Beckman LJ, Raffals LL, Papadakis KA, Kane SV. Predictors of Health-Related Quality of Life and Adherence in Crohn’s Disease and Ulcerative Colitis: Implications for Clinical Management. Dig Dis Sci 2015; 60: 1366-74.

  18. Mattar MC, Lough D, Pishvaian MJ, Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res 2011; 4: 53-61.

  19. Tabibian JH, Streiff MB. Inflammatory bowel disease-associated thromboembolism: a systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis. Inflamm Bowel Dis 2012; 18: 161-71.

  20. Teeples TJ, Tabibian JH. Images in clinical medicine. Mesenteric abscess in Crohn’s disease. N Engl J Med 2013; 368: 663.

  21. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. SCENIC International Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel Disease. Gastroenterology 2015; 148: 639-51 e628.

  22. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 489-501 e426.

  23. Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, Faigel DO, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006; 63: 558-65.

  24. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert review of gastroenterology & hepatology 2013; 7: 103-14.

  25. Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, Schrumpf E, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40: 815-22.




2020     |     www.medigraphic.com